Thursday, January 22, 2026

CRISPR-Cas systems against carbapenem resistance: from proof-of-concept to clinical translation.

Authors: Tsolakidou PJ.

DOI: 10.3389/fmicb.2025.1725247

Abstract Summary

CRISPR technology shows promise against drug-resistant superbugs. Scientists are developing Cas9, Cas13, and Cas3 systems to selectively eliminate carbapenem-resistance genes from dangerous bacteria. Conjugative plasmids can deliver these gene editors between bacteria without lab manipulation, while phage-based therapies have reached early clinical trials. Key challenges include delivery efficiency and ecological safety, but novel platforms like nanoparticles and engineered vesicles may overcome current limitations.

Why Brain? 🧠

CRISPR gene-editing tools can selectively eliminate carbapenem-resistance genes in deadly bacteria, offering a precise alternative to antibiotics as some approaches enter early human trials.

License: CC BY.


The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.

share this recipe:
Facebook
X
Email
Print

Still hungry? Here’s more